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Abstract
Background: Genome-wide association studies (GWAS) require large sample sizes to obtain adequate statistical power, but
it may be possible to increase the power by incorporating complementary data. In this study we investigated the feasibility
of automatically retrieving information from the medical literature and leveraging this information in GWAS.
Methods: We developed a method that searches through PubMed abstracts for pre-assigned keywords and key concepts,
and uses this information to assign prior probabilities of association for each single nucleotide polymorphism (SNP) with the
phenotype of interest - the Adjusting Association Priors with Text (AdAPT) method. Association results from a GWAS can
subsequently be ranked in the context of these priors using the Bayes False Discovery Probability (BFDP) framework. We
initially tested AdAPT by comparing rankings of known susceptibility alleles in a previous lung cancer GWAS, and
subsequently applied it in a two-phase GWAS of oral cancer.
Results: Known lung cancer susceptibility SNPs were consistently ranked higher by AdAPT BFDPs than by p-values. In the
oral cancer GWAS, we sought to replicate the top five SNPs as ranked by AdAPT BFDPs, of which rs991316, located in the
ADH gene region of 4q23, displayed a statistically significant association with oral cancer risk in the replication phase (per-
rare-allele log additive p-value [ptrend]=2.5610
23). The combined OR for having one additional rare allele was 0.83 (95% CI:
0.76–0.90), and this association was independent of previously identified susceptibility SNPs that are associated with overall
UADT cancer in this gene region. We also investigated if rs991316 was associated with other cancers of the upper
aerodigestive tract (UADT), but no additional association signal was found.
Conclusion: This study highlights the potential utility of systematically incorporating prior knowledge from the medical
literature in genome-wide analyses using the AdAPT methodology. AdAPT is available online (url: http://services.gate.ac.uk/
lld/gwas/service/config).
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Introduction
Risk effects of common susceptibility variants of complex
disorders - including most cancers - are generally small (i.e.
OR,1.5) [1] and genome-wide association studies (GWAS)
require a stringent significance threshold (e.g. p-value,10
27)
due to the burden of multiple testing. Thus, GWAS for cancer risk
require large sample sizes in order to have sufficient statistical
power. It is therefore problematic to conduct GWA studies of less
common cancers for which recruiting an adequate number of
cases is difficult. There may be benefit in incorporating additional
evidence gathered through complementary experiments or other
sources of information. Such information can be incorporated with
GWAS results using simple Bayesian methods [2] for instance the
method developed by Wakefield [3]. This uses the approximate
Bayes factor (ABF), estimated using beta estimates and standard
errors of gene variant to disease associations, together with the
prior odds for the null hypothesis to generate the Bayes False
Discovery Probability (BFDP). Hence, the BFDP provides an
estimate of the probability that the observed result represents a
false positive association, and can be used in place of p-values
when ranking or otherwise evaluating association results. The
main difficulty in implementing such an approach in GWAS is
assigning relevant and realistic prior probabilities of association
with disease for each investigated single nucleotide polymorphism
(SNP).
Potential prior information for gene-disease relationships can be
retrieved from various sources, for example expression quantita-
tive trait loci (eQTL) experiments, pathway ontology databases,
and literature scans [2]. In recognizing that a large number of
susceptibility variants identified through GWAS reside near
plausible candidate genes [4], we hypothesized that it is possible
to extract prior knowledge from the text-based medical literature
in order to increase the statistical power of detecting susceptibility
SNPs for which such information is available.
In order to evaluate the feasibility and potential benefit of such a
study design, we developed a method that automatically retrieves
relevant data from PubMed abstracts in order to generate prior
probabilities of a genome-wide investigated variants being
involved in a specific disease, and subsequently incorporates this
data with the association results from GWAS using the BFDP
framework [5], the Adjusting Association Priors with Text
(AdAPT) method. AdAPT was subsequently applied in a GWAS
of oral cancer (OC) [6–10].
Results
Power calculations for BFDP and p-values
As described by Wakefield [3,11] the BFDP estimate can be
used as means of evaluating and reporting noteworthy associations
in its own right. However, we envisage a wider adoption of a
hybrid, two-phase study design, in which SNPs that are deemed
sufficiently ‘‘noteworthy’’ according to their BFDP estimates are
chosen for replication in an independent study population and
evaluated using the replication p-values. For instance, adopting a
BFDP cut-off of 0.8 when selecting SNPs for replication implies
that a false non-discovery is four times as costly as a false discovery,
or that we expect on average one out of five SNPs chosen for
replication to be associated with the disease. False non-discovery
includes any ‘‘true’’ susceptibility SNP present in the dataset that
did not attain a BFPD of below 0.8. Here we consider true
susceptibility SNPs being associated with the phenotype of interest
in statistically robust and reproducible manner, although do imply
functional causality. In order to evaluate the statistical power of
selecting susceptibility SNPs of oral cancer using our case-control
series of 791 cases and 7,012 controls, we evaluated the statistical
power according to (equation [eq.] 9, see Statistical analyses).
These power calculations were based on 300,000 SNPs being
evaluated in the GWAS, that 100 true susceptibility SNPs of oral
cancer were included in the data set and evenly distributed across
the prior categories (i.e. N*=100, N1*=N 2*=N 3*=33.3).W e
considered three prior categories (J=3) and the overall SNPs in
the GWAS being distributed as C1=0.875, C2=0.10, and
C3=0.025. We can calculate the prior odds of the null hypothesis
for the three prior categories under these assumptions according to
(eq. 7) which gives PO1=7874, PO2=899, and PO3=224. The
statistical power for achieving a BFDP of 0.8 for SNPs with an OR
of 1.25 in each of the three prior categories is shown in Figure 1.
For comparison, we include the power for using BFDP assuming
the same N* but with all SNPs assigned the same prior. Under
these assumptions the power to detect associated SNPs in C3 or C2
is increased, while sacrificing some power for those in C3. This
demonstrates the potential benefits of adopting such a Bayesian
framework in GWAS, if the categories and their priors are
appropriately chosen.
We also included supplementary power calculations in Figure
S1 by varying the assumed number of true susceptibility SNPs.
Validation of AdAPT methodology
In order to perform an initial proof-of-principle evaluation of the
AdAPT–BFDP method, we applied it to data from our previously
reported lung cancer GWAS [12]. Firstly, we used the AdAPT
web service to generate prior probabilities for SNPs based on the
medical literature (see Material and methods). The keywords were
grouped by priority, the first group including overarching words
that are specific to lung cancer, e.g. ‘lung cancer’ and ‘lung
carcinoma’, the second group included more general words
specifically relevant to lung cancer, e.g. ‘smoking’, ‘nicotine’, ‘non-
small cell carcinoma’, and the third group included more generic
words that are not exclusively important for lung cancer, but for
cancer in general, e.g. ‘carcinogen’, ‘DNA damage’, ‘neoplastic’,
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abstracts for each gene and assigned prior odds according to (eq.
7). We only included literature published before the date of the
first lung cancer GWAS [12] in order to avoid bias.
Secondly, we split our original lung cancer GWAS into a series
of smaller subsets to simulate GWAS with lower statistical power.
This was performed by randomly selecting (equal distributions of
cases and controls) 50% and 75% of the total data series 100 times.
GWAS analysis for all subseries was then carried out and results
ranked by p-value and by BFDP using priors estimated using the
AdAPT web service. We compared the ranking by BFDPs and p-
values within each subseries (50%, 75% or 100%) for five
susceptibility variants identified by lung cancer GWAS that have
been independently replicated in multiple studies (Table 1) [12–
14]. Out of these five SNPs, four were assigned elevated priors that
resulted in clear improvements in ranking when using the BFDP
estimates compared to the p-values. For instance, when sampling
75% of the complete data set the rs401681 SNP on 5p15.33 was
ranked at 2709 by p-value and at 664 by BFDP.
Novel genome-wide association analyses
We subsequently performed a GWAS of oral cancer. This scan
followed a two phase design, with the association results of the
genome-wide discovery phase ranked by AdAPT-BFDPs.
Discovery phase. In the discovery phase, after quality
control, genome-wide analysis was carried out in 791 cases and
7,012 controls. Q-Q plot analysis did not indicate any notable
inflation overall (linflation=1.04), suggesting that hidden popula-
tion substructures had little or no impact on the results of the
genome-wide analysis (Figure S2). AdAPT was employed based on
Pubmed abstracts, using key words relevant to oral cancer (Table
S1) in a manner comparable to the lung cancer experiment
outlined above. Out of 293,211 evaluated SNPs, 149,998 were
grouped as C1, 137,576 were grouped as C2, and 6,637 were
grouped as C3. We evaluated the individual SNP BFDP estimates
using a basic sensitivity analysis approach by three distinct set of
assumptions regarding the number of true susceptibility SNPs,
namely N*=50, N*=100, and N*=500. We applied a BFDP
threshold of 0.80 for selecting SNPs for replication, and six SNPs
met this criterion for all N* (Table 2). Because we had already
evaluated and confirmed the 6
th ranked SNP (rs1789924, AHD1C)
in a previous study of overall UADT cancer (Table 2) [11], five
SNPs were selected for replication. These SNPs included
rs1888732 on 1p22.3 (log additive odds ratio [ORtrend]=0.70,
95% confidence interval [95% CI]:0.61–0.81, BFDP100=0.06),
rs3130559 on 6p21.33 (ORtrend=0.76, 95% CI: 0.65–0.88,
BFDP100=0.57), rs10801805 on 1p22.2 (ORtrend=1.30, 95%
CI: 1.16–1.46, BFDP100=0.58), rs991316 on 4q23 (OR-
trend=0.81, 95% CI: 0.72–0.91, BFDP100=0.62), and
rs10008621 on 4q35.2 (ORtrend=0.72, 95% CI: 0.60–0.86,
BFDP100=0.66).
Replication analysis. After quality control and statistical
analysis within the replication series, only rs991316 displayed a
statistically significant association with oral cancer risk (per-rare-
allele log additive p-value [ptrend]=2.5610
23, Table 2). A graph of
2log10 p-values and pair-wise r
2 estimates for SNPs included in
the GWAS phase of the ADH gene region is given in Figure 2. The
OR compared to the major homozygotes of the combined dataset
(GWAS+replication data) were 0.88 (95% CI: 0.78–1.01) for the
heterozygotes, and 0.67 (95% CI: 0.57–0.79) for the minor
homozygotes. The OR associated with having one additional rare
allele (log-additive model) was 0.83 (95% CI: 0.76–0.90), and this
association was independently replicated (ptrend,0.05) in the two
largest replication studies (The Latin America and ORC studies,
Table S1, pheterogeneity=0.67). The rs991316 SNP is located in a
region of 4q23 which includes several genes encoding different
Figure 1. Comparison of the statistical power for three categories of prior odds for the null hypothesis when evaluating the
noteworthiness of SNPs by BFDP. These power calculations assume an evaluation of 300,000 SNPs of which 100 are truly associated with the
outcome and distributed evenly across three prior categories, respectively. The overall distribution of SNPs across the three prior categories is
assumed to be [87.5%; 10%; 2.5%]. Flat PO assumes one single prior category.
doi:10.1371/journal.pone.0036888.g001
Prior Info from Literature in Oral Cancer GWAS
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36888alcohol dehydrogenase (ADH) subunit genes, i.e. the ADH6, ADH1A,
ADH1B, ADH1C, and ADH7 genes. In the AdAPT literature
search, two genes were assigned as potentially relevant for the
rs991316 SNP, ADH1C and ADH7, located approximately 49 kb
centromeric and 11 kb telomeric of rs991316, respectively. SNPs
in this region (i.e. rs1229984 [ADH1B], rs1789924 [ADH1C] and
rs971074 [ADH7]) have previously been associated with overall
UADT cancer. However, rs991316 was poorly correlated with
rs1229984, rs1789924 and rs971074 (r
2,0.05), and conditioning
the risk analysis on these SNPs did not notably affect the OR of
rs991316 (ORadjusted,0.84). Furthermore, we investigated if
rs991316 was also associated with other UADT subsites apart
from oral cancers, but stratified analysis revealed that the risk
effect of rs991316 were confined to oral cancer (oral cavity and
oropharynx), but not cancers of the hypopharynx, larynx or
esophagus (pheterogeneity=0.03, Figure 3). Taken together, these
results suggest that the rs991316 SNP is associated specifically
with oral cancer, but not with other UADT cancers within this
population, and that the association is independent of previously
detected susceptibility SNPs of UADT cancer in this region.
Furthermore, this heterogeneity in risk effects between oral and
other UADT cancers may also explain why this variant was not
detected in our original GWAS of overall UADT cancer.
Stratified analyses
We conducted further stratified risk analyses for rs991316
(Figure 3), but apart from the heterogeneous risk effect on oral
cancers overall, compared to other UADT cancers (pheterogeneity
=0.03), no clear effect modifications were observed (pheterogeneity
.0.10). Some suggestive evidence for effect modification by
gender was observed (pheterogeneity=0.11), the association with risk
being stronger among men. Some indications of tobacco smoking
and alcohol intake also modifying the association with risk was also
observed, with risk becoming more pronounced with higher levels
of smoking and drinking, but formal tests did not support
interaction (pinteraction=0.15 and 0.10 for smoking and alcohol
intake, respectively). Further adjusting the main rs991316 risk
analysis for drinking and smoking did not modify the OR estimates
(data not shown).
Discussion
We report a method for retrieving information from the text-
based medical literature and estimating prior probabilities of
association for all SNPs investigated in GWAS, the Adjusting
Association Priors with Text (AdAPT) method. The priors can
subsequently be incorporated with association results into a
Bayesian measure of the noteworthiness of association for each
SNP to disease association.
Table 1. Comparison of GWAS ranking of validated lung cancer susceptibility SNPs by p-values and BFDPs for known susceptibility
loci of lung cancer.
SNP ID/ Ranking
4
Gene region/ OR (95% CI)
1/ By p-values
5 By BFDPs
7
Locus Pr(H1)
2 Sampling
3 Median (Range)
6 Mean (Stdev) Median (D, Range)
6 Mean (D, Stdev)
rs1051730 1.30 (1.19–1.43) 50% 941 (8–32308) 8604 (25454) 192 (D: 2749, 3–7283) 1779 (D: 26825, 4772)
CHRNA3 1.4610
23 (top) 75% 10 (2–1240) 312 (1722.6) 3 (D: 27, 1–293) 77 (D: 2235, 421)
15q25.1 100% 2 2 2 (D:0 ) 2( D:0 )
rs4324798 1.44 (1.22–1.69) 50% 7305 (167–121021) 26429 (46409) 16542 (D: 9237, 420–133949) 35963 (D: +9534, 44376)
N/A 2.0610
24 (low) 75% 824 (11–8320) 3427 (14488) 1450 (D: 626, 21–14871) 4917 (D: +1490, 15611)
6p22.1 100% 4 4 5 (D:1 ) 5( D:1 )
rs401681 0.84 (0.77–0.92) 50% 24870 (427–173666) 47681 (57625) 5416 (D: 219455, 82–35587) 9997 (D: 237684, 11336)
TERT/CLPTM1L 1.4610
23 (top) 75% 2709 (38–25157) 8963 (22286) 664 (D: 22045, 13–6017) 2111 (D: 26852, 4706)
5p15.33 100% 73 73 30 (D: 243) 30 (D: 243)
rs2736100 1.18 (1.08–1.29) 50% 17573 (231–168022) 40226 (53442) 3864 (D: 213709, 46–35187) 8809 (D: 231417, 10852)
TERT/CLPTM1L 1.4610
23 (top) 75% 2317 (142–38366) 9966 (21009) 581 (D: 21736, 27–9771) 2482 (D: 27484, 4942)
5p15.33 100% 76 76 32 (D: 244) 32 (D: 244)
rs3117582 1.31 (1.13–1.52) 50% 19589 (185–224392) 50985 (68903) 2850 (D: 216739, 45–20856) 5825 (D: 245160, 6601)
BAT3 1.4610
23 (top) 75% 2648 (57–44765) 11419 (23087) 482 (D: 22166, 15–6513) 1647 (D: 29772, 2792)
6p22.33 100% 121 121 34 (D: 287) 34 (D: 287)
1)Odds ratios were estimated based on the complete dataset (100%).
2)Pr(H1) refers to the prior probability of the alternative hypothesis (prior probability of SNP being associated with lung cancer) and was calculated based on the AdAPT
webervice being run on Entrez gene riftexts and Pubmed Abstracts, respectively. The priors were calculated in three categories (low/mid/high). See further details on
the statistical framework for performing these calculations in the Methods section.
3)50% and 75% of data were randomly sampled from the complete dataset 100 times.
4)For each randomly sampled sub-dataset we performed logistic regression and estimated odds ratios along with 95% confidence intervals, p-values and approximate
bayes factors. These were subsequently used to estimate BFDPs in order to compare the ranking of known susceptibility SNPs of lung cancer using two ranking
methods, by p-values and by BFPDs.
5)P-values were estimated using logistic regression models.
6)Median and mean ranking were based on the results from 100 randomly sampled datasets, D indicates the change in ranking compared to p-value based ranking, the
range refers to the highest and lowest ranking observed, respectively.
7)BFDP (PubMed abstracts) were calculated using priors that were estimated by running the AdAPT web service on Pubmed abstracts (published before January 2008).
doi:10.1371/journal.pone.0036888.t001
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approach is agnostic, thus offering the ability to detect novel
susceptibility loci without inferring prior beliefs regarding the
importance of specific genes (e.g. compare with the candidate gene
approach). However, many genetic susceptibility variants detected
in GWAS reside near plausible candidate genes, and the AdAPT-
BFDP method gives an opportunity to leverage this information in
an automatic fashion. AdAPT automatically searches through
PubMed abstracts for relevant prior evidence of involvement in
the disease in question. Coupled with the BFDP statistical
framework, AdAPT incorporates the prior information with the
association results from the GWAS, thus giving SNPs near genes
previously implicated in the disease of interest a higher ranking.
We initially validated AdAPT-BFDP based on GWAS data of
lung cancer and noted that validated susceptibility SNPs were
consistently ranked higher by AdAPT-BFDP estimates than by p-
values (Table 1). The method was subsequently applied in a
modestly sized GWAS of oral cancer (approximately 800 cases)
with poor statistical power to detect the intermediate risk effects
typically observed in GWAS (#40% statistical power for choosing
a SNP for replication at p,10
25 assuming an OR of 1.25). By
ranking the association results according to AdAPT-BFDPs and
replicating the top five SNPs, we identified a novel susceptibility
variant within the known oral and UADT cancer susceptibility
region of the ADH gene cluster on 4q23. We investigated if the
association of rs991316 could be explained by linkage disequilib-
rium with previously identified risk variants of overall UADT
cancer on this locus [8,15], including rs1229984, rs1789924 and
rs971074, but their pair-wise correlations were low and condi-
tioning the risk analysis on these SNPs did not affect the OR
estimate of rs991316. Furthermore, haplotype analysis clearly
showed that the variant alleles of these SNPs were located on
different haplotypes (data not shown), thus further strengthening
the independency inference of these susceptibility SNPs. Impor-
tantly, the rs991316 SNP was not associated with other UADT
cancers (Figure 3), hence supporting the notion of a novel
association, as evidence for association with other UADT cancer
sites has been noted with the previously detected susceptibility
SNPs.
We acknowledge that any method that takes non-curated prior
information into account in association studies is imperfect and
subject to various biases [2], and the AdAPT-BFDP method has
several limitations. As AdAPT searches PubMed abstracts for the
presence of pre-assigned keywords and semantically related
concepts, the final result (ranking by BFDPs instead of p-values)
will privilege SNPs in the proximity of genes that have been
studied in relation to the endpoint of interest. As shown in Figure 1,
there is a loss in statistical power for SNPs for which no relevant
prior information is available. This penalty imposed on novel
genes and gene deserts would seem contradictory to the agnostic
nature of a GWAS, even though strong association signals will
remain highly ranked using either method.
Table 2. Summary results for the six SNPs selected for replication in oral cancer GWAS. Ranking was based on the Bayesian False
Discovery Probability (BFDP).
Discovery phase Replication phase
Locus/ SNP ID/ Cases/controls: 791/7012
a Cases/controls: 1046/2131
b
Gene region Alleles: Freq.
c
Odds ratio
(95% CI)
d P-value
d Prior
e P rank
fBFDP (range)
g
BFDP
rank
h
Odds ratio (95%
CI)
i P-value
i P-het
j
1p22.3 rs1888732 0.70 2.3610
27 2.2610
24 1 0.06 1 0.92 0.21 3.5610
23
LMO4 A/G: 0.74/0.26 (0.61–0.80) (0.01–0.11) (0.81–1.05)
6p21.33 rs3130559 0.76 2.0610
24 5.0610
23 68 0.57 2 1.1 0.21 7.0610
24
PSORS1C1 C/T: 0.79/0.21 (0.65–0.88) (0.20–0.72) (0.95–1.28)
1p22.2 rs10801805 1.30 6.4610
26 2.2610
24 2 0.58 3 0.99 0.89 1.1610
23
N/A G/A: 0.65/0.35 (1.16–1.46) (0.21–0.73) (0.88–1.12)
4q23 rs991316 0.81 2.2610
24 5.0610
23 76 0.62 4 0.84 2.5610
23 0.6
ADH1C/ADH7 C/T: 0.54/0.46 (0.72–0.91) (0.24–0.77) (0.75–0.94)
4q35.2 rs10008621 0.72 3.3610
24 5.0610
23 112 0.66 5 0.98 0.79 0.02
FAT1 C/T: 0.87/0.13 (0.60–0.86) (0.27–0.79) (0.81–1.18)
4q23 rs17899247 1.23 3.0610
23 5.0610
23 98 0.67 6 Replicated previously
ADH1C C/T: 0.59/0.41 (1.10–1.38) (0.29–0.80) by McKay et al.
11
a)Total number of cases and controls included in the final GWA analysis (Table S2).
b)Total number of cases and controls included in the replication analysis.
c)Major and minor alleles, with corresponding allele frequencies in controls.
d)OR, 95% CI and p-values were estimated for the per-rare-allele log-additive genetic model by unconditional logistic regression, adjusting for sex and country (see
methods).
e)Prior probability of association (prior for the alternative hypothesis H0) based on the ADAPT literature search (see methods).
f)GWAS ranking based on p-values.
g)The Bayesian False Discovery Probability (BFDP) was estimated based on the association results and the prior probability of association (see methods). The point BFDP
estimate corresponds to 100 true susceptibility SNPs assumed to be included in the dataset that are evenly distributed across the prior categories. The range refers to a
sensitivity analysis of the BFDP by varying the assumed number of true susceptibility SNPs in the dataset. The bottom and upper boundaries were estimated by
assuming 500 and 50 true susceptibility SNPs, respectively.
h)GWAS ranking based on BFDP estimates.
i)OR, 95% CI and p-values were estimated for the per-rare-allele log-additive genetic model by unconditional logistic regression, adjusting for sex and study center (see
methods).
j)P-heterogeneity indicates differences in OR between the discovery and replication phases, and was derived from the Cochran’s Q test.
doi:10.1371/journal.pone.0036888.t002
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36888The method is also sensitive to the assumed number of truly
associated SNPs (N*). Increasing this number will allow more
SNPs to pass the BFDP threshold, but it will not change their
ranking. In a two phase design where the number of SNPs
retained for the second phase is determined by the second-stage
power [16], only the relative ranking in the first stage is relevant
and the choice of N* is immaterial. By contrast, the proportion of
truly associated SNPs in each prior category influences the ranking
by changing the prior probability of association for each variant.
Further, the current implementation of AdAPT uses a relatively
simple text mining algorithm and, as such, remains relatively
crude. For example, it does not take the frequency of key-word
matches into account when assigning the priors, nor does it take
into account if individual studies report positive or negative study
results. Such strategies will be evaluated in future implementations
of AdAPT, as well as methods aiming to expand keywords into
semantically related concepts. In addition, AdAPT currently
assigns individual SNPs to genes simply based on their location,
e.g. if they are within 50 kb from a given gene. Here it would seem
useful to also take linkage disequilibrium into account, as has been
implemented in the Gene Relationships Across Implicated Loci
(GRAIL) methodology [17]. Similarly to AdAPT, GRAIL uses
text mining of PubMed abstracts to prioritize SNPs in GWAS, but
does so by identifying genes that are functionally related to
multiple other genes to a higher extent than what would be
expected by chance. While the GRAIL methodology has the
advantage of not requiring the phenotype of interest to be studied
in relation to a particular gene before, nor does it benefit when
such information is available. Hence, it seems both the AdAPT
and GRAIL methodologies may prove useful together, or on their
own, in prioritizing SNPs from initial GWA scans for further
follow-up.
Importantly, we envisage using the AdAPT-BFDP method as
complementary tool - rather than as a replacement - to the more
traditional GWAS approach (i.e. p-value ranking), e.g. by initially
using p-value based ranking to detect genetic loci in an agnostic
manner, and subsequently, the AdAPT-BFDP methodology to
further leverage the data with a potential to detect variants that
may otherwise be overlooked. While it is generally not recom-
mended to conduct underpowered studies, the AdAPT-BFDP
method may also assist detection of susceptibility loci when the
statistical power is poor, for instance in stratified genome-wide
analysis such as in the underpowered oral cancer GWAS. Indeed
the rs991316 SNP was ranked 76
th by p-values, and this
susceptibility SNP would not have been included in the replication
phase had we adopted to replicate only the very top ranked
variants by p-values. Furthermore, if the number of SNPs selected
for replication had been sufficiently deep to include rs991316, the
statistical evidence for replication (Ptrend=2.5610
23) would not
have been deemed noteworthy after adjustment for multiple
testing in the replication phase (i.e. a Bonferroni adjusted
significance threshold of p=0.0007). Hence, it appears that the
AdAPT-BFDP strategy assisted the detection and validation of the
rs991316 variant. The AdAPT process can also be easily adapted
to provide prior information of overall genes rather than
individual SNPs, and as such, may also be useful in genomic
applications, such as exome or genome based sequencing studies.
Furthermore, several sources of information could potentially be
included within the Bayesian framework, for example pathway
ontology databases, other text based methods including GRAIL,
or complementary experiments such as genome-wide eQTL
analysis [18].
Conclusions
This study confirms that it is possible to incorporate compre-
hensive prior information in an automated fashion to assist in
prioritizing SNPs in GWAS for further follow-up, in this case from
Figure 2. Association results of the SNPs included in the GWAS of oral cancer (by p-values), pair-wise r
2 estimates with rs991316,
and recombination rates, for SNPs in the ADH gene region on 4q23. P-values indicating the strength of association for each SNP in the GWAS
with oral cancer are shown on the 2log10 scale (left Y-axis), against their positions on chromosome 4 (Build 36.3). The color of each point and SNP
represent the degree of linkage disequilibrium (r
2) with rs991316 according to HapMap phase II CEU data. Highlighted in the figure are rs1229984,
rs1789924 and rs971074, which have been reported to be associated with UADT cancers previously, as well as the rs991316 SNP which was
discovered to be associated specifically with oral cancer in the current study. rs1229984 was not genotyped, nor tagged by a proxy variant on the
HumanHap300 BeadChip but was genotyped by Taqman assay in the same samples from Central Europe and ARCAGE studies as included in the
discovery phase of current GWAS, and r
2 between rs1229984 and rs991316 was estimated in the 3,513 controls from Central European and ARCAGE
studies. Recombination rates across the region are shown by the light blue line plotted against the right y axis. Genes in the region are represented
with arrow heads indicating the direction of transcription.
doi:10.1371/journal.pone.0036888.g002
Prior Info from Literature in Oral Cancer GWAS
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36888the text-based medical literature using the AdAPT-BFDP method-
ology. In support of this, we report a novel susceptibility SNP of oral
cancer in the ADH gene region of 4q23, which was associated with
risk independently of previously identified risk SNPs of overall
UADT cancer in this region. We have made the AdAPT
methodology available to the research community through a web
service (url: http://services.gate.ac.uk/lld/gwas/service/config).
Materials and Methods
Ethics statement
All participants gave written informed consent to participate in
the study and the IARC Ethics Committee (IEC) approved this
research.
Retrieving information from the medical literature using
AdAPT
In order to extract relevant information from the medical
literature in a comprehensive and unbiased fashion, we developed
the Adjusting Association Priors with Text (AdAPT) method.
AdAPT identifies relevant PubMed abstracts for each RefSeq gene
through the Entrez gene database (url: http://www.ncbi.nlm.nih.
gov/gene), where all studies that have investigated a particular
gene are cross referenced with PubMed. For this study, any gene
within 50 000 base pairs of a SNP was mapped, together with the
abstracts linked to that gene. It is also possible to use the GeneRif
texts, which are short and manually annotated summaries of each
research paper, in place of PubMed abstracts. These GeneRif texts
are directly provided in the Entrez gene database. All relevant
abstracts are subsequently mined for keywords and key concepts
relating to important features of the disease or phenotype of
interest, including etiological and mechanistic factors. This mining
is carried out using GATE (url: http://gate.ac.uk) [19], which
splits abstracts into sentences, tokenizes the sentences into
individual terms, finds the part of speech for tokens, and breaks
each token into its main component (morphological root).
Abstracts were also mapped to UMLS concepts using MetaMap
[20,21]. Tokens and concepts were stored in a GATE Mimir index
Figure 3. Forest plot showing overall and stratified association results of the rs991316 SNP with oral cancer (oral cavity and
oropharyngeal cancer). a) Apart from the OR for CT heterozygotes and TT homozygotes, which were estimated relative the major CC
homozygotes, all OR and 95% CIs were estimated using the log-additive model, adjusting for age, gender and center. All subjects from the genome-
wide and replication phases with available co-variates were included in this analysis (not generic controls). The overall OR for cancers of oral cavity
and oropharynx is shown by the dotted vertical line. b) P for heterogeneity indicates differences in OR between strata and was derived from the
Cochran’s Q test. c) Never drinkers were subjects that either reported 0 g alcohol intake per day, or reported being never drinker, light drinkers
consumed .0 and ,6.06 g alc./day, intermediate drinkers consumed .6.06 and ,46.3 g alc./day, and heavy drinkers consumed .46.3 g alc./day. d)
Hypopharynx, larynx, and esophagus cases were not included in the analyses above.
doi:10.1371/journal.pone.0036888.g003
Prior Info from Literature in Oral Cancer GWAS
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36888to facilitate fast retrieval and to store mapping between individual
SNPs and relevant abstracts [22]. Keywords for mining were also
processed with GATE to give morphological roots and the
presences of these were subsequently checked in the index for each
SNP.
We assigned keywords into one of three groups, G1, G2 and
G3, group G1 containing words of the highest importance for the
phenotype, and group G3 containing relevant, but subjectively less
important words. Based on the presence of relevant keywords,
each gene and proximal SNPs can logically be assigned to one of 8
possible binary combinations of G1, G2 and G3. For our purposes
we defined three categories (Ci, i=1,2,3):
1. C1={Not G1, Not G2, Not G3}
2. C2={At least one of G1,G 2,G 3 but not all }
3. C3={G1,G 2,G 3}.
We developed a web service that allows a user to conduct key
word queries over an arbitrary set of SNPs in a timely manner, e.g.
a list of SNPs included on a particular genome-wide BeadChip
(url: http://services.gate.ac.uk/lld/gwas/service/config). This re-
turns a classification over all 8 possible categories, allowing further
collapsing by the user. We also provide an R-script that estimates
the prior probabilities for each SNP and re-ranks the GWAS
results according to the BFDP estimates. This will allow
investigators to freely apply the AdAPT methodology without
uploading their association results online (url: http://services.gate.
ac.uk/lld/gwas/service/rscript). The R-script also allows the user
to redefine the grouping of prior categories.
Statistical analysis
Assigning prior probabilities of association and the
Bayesian false discovery probability (BFDP). In order to
estimate the Bayesian false discovery probability (BFDP), as
proposed by Wakefield [5], we first need to estimate the Bayes
factor, the relative likelihood of the data y under either the null
hypothesis (no association, H0) or the alternative (SNP associated
with the disease, H1):
BF~
Pr yjH0 ðÞ
Pr yjH1 ðÞ
: ð1Þ
Estimating the Bayes factor is computationally difficult because it
requires the complete specification of both the data-generating
mechanism (the likelihood), the prior distribution for all param-
eters of the model, and the calculation of multidimensional
integrals. To overcome these difficulties Wakefield introduced the
approximate Bayes factor (ABF). For a generic SNP, in the case of
a single summary parameter h (e.g. a log odds ratio) with estimate
^ h h, standard error
ﬃﬃﬃﬃ
V
p
, and a normal prior N(0,W) on h:
ABF~
Pr ^ h hjH0
  
Pr ^ h hjH0
   ~
1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1{r
p exp {
Z2
2
r
  
ð2Þ
Where Z is the normal statistic Z~^ h h=
ﬃﬃﬃﬃ
V
p
and r is the ratio
between the prior and total variance (r=W/(V+W)). The estimate
^ h h and standard error
ﬃﬃﬃﬃ
V
p
are readily available from standard
regression output [5]. The Bayesian False Discovery Probability is
defined as
BFDP~
ABF|PO
ABF|POz1
ð3Þ
where PO is the prior odds for H0. It provides a means of
evaluating the noteworthiness of SNP-endpoint associations that
takes both the association result and prior evidence into account
[5].
In order to incorporate the prior information gained in the
AdAPT literature search (C) into the BFDP we need to estimate the
prior odds of the null hypothesis given the AdAPT results as
PO~
Pr H0 C j ðÞ
Pr H1 C j ðÞ
, ð4Þ
where C is a generic prior category. Each SNP evaluated in a
GWAS will fall into one of J prior categories (Cj), i.e. as shown
above. In order to estimate (eq. 4) we need to compute Pr(H0|Cj)
and Pr(H1|Cj), j=1,…,J. We can write the prior probability for a
SNP to fall into prior category j as
Pr Cj
  
~Pr Cj H0 j
  
Pr H0 ðÞ zPr Cj H1 j
  
Pr H1 ðÞ : ð5Þ
We assume that N SNPs are being evaluated in the GWAS, and
that the number of SNPs which are truly associated with the
endpoint in each prior category is N 
j : We can then write the
overall probability of the alternative hypothesis as
Pr H1 ðÞ ~1{Pr H0 ðÞ ~
P J
j~1
N 
j =N: The AdAPT literature search
will provide the overall distribution of SNPs across the prior
categories, Nj, and we can calculate, as well as
Pr Cj H1 j
  
~N 
j =
P J
j~1
N 
j : From (eq. 5) we have
Pr CjjH0
  
~
Nj{N 
j
N{
P
N 
j
: ð6Þ
According to Bayes theorem (with Cj acting as the data) we can
write the prior probabilities of the null and alternative hypotheses
given the AdAPT search as Pr H0jCj
  
~Pr CjjH0
  
Pr H0 ðÞ =
Pr Cj
  
and Pr H1jCj
  
~Pr CjjH1
  
Pr H1 ðÞ =Pr Cj
  
respectively,
which gives the prior odds of H0 given a SNP in prior category j.
POj~
Pr H0jCj
  
Pr H1jCj
   ~
Pr CjjH0
  
Pr H0 ðÞ
Pr CjjH1
  
Pr H1 ðÞ
~
Nj{N 
j
N 
j
, ð7Þ
the difference between the total number of SNPs in category j and
the number of truly associated SNPs in category j, divided by the
number of truly associated SNPs in category j. We can now
calculate the BFDP which not only takes the strength of association
into account, but also the statistical power and the prior
probability of association according to the AdAPT literature
search. In making a final decision we may choose to reject H0 if the
BFDP falls below a threshold c.
In order to evaluate the statistical power q to achieve a BFDP of
c, given y and POj we need to evaluate q~Pr(BFDPv
c y,POj,MAF)
    which is equivalent to
Pr(logit BFDP ðÞ vlogitcy,POj,MAF): ð8Þ
If we substitute BFDP for the expression in (eq. 3) we have
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Here Z
2 is a non-central x
2 with 1 degree of freedom and non-
centrality parameter h
2/V, which is equivalent to
Z*N h=
ﬃﬃﬃﬃ
V
p
,1
  
; under H0 we have the special case Z2*x2
1,
i.e. a chi-squared random variable with 1 degree of freedom.
Frequentist analysis
The association between each genetic variant and cancer risk
was estimated using the per-rare-allele log-additive genetic model.
Odds ratios (OR) were estimated by unconditional logistic
regression, adjusting for gender and country of recruitment
(GWAS), or for gender, age and study center (replication).
For the GWAS, quantile-quantile plot analysis of p-values was
conducted to evaluate if the genome-wide analysis was subject to
systematic bias. These analyses were conducted using PLINK and
R [23].
In the replication phase, data were stratified by study group and
the homogeneity of OR between strata was tested using Cochran’s
Q-test. These analyses were conducted using SAS 9.2 software,
and all p-values were two-sided.
Study population
An initial proof-of-principle analysis was carried out using data
from a GWAS of lung cancer including 1,989 cases and 2,625
controls. This study was conducted in six central European
countries and of which details have been previously published
[12].
Subsequently, we conducted a novel analysis using data
generated in an oral cancer GWAS. Genome-wide genotyping
was performed in two European based multi-centre case-control
studies (Table S2), the International Agency for Research on
Cancer (IARC) central Europe (CE) study conducted from 2000 to
2002, in 6 centers from 5 countries [8,12,24] and the ARCAGE
(Alcohol-Related Cancers and Genetic susceptibility in Europe)
multi-centre case control study conducted by IARC from 2002 to
2005 in 12 centers from 9 European countries [8,12,25].DNA of
sufficient quality and quantity for genome-wide genotyping was
available for a total of 859 oral cancer cases (squamous cell
carcinomas) and 3,999 controls from these two studies. Oral
cancer cases included cancer of the oral cavity and oropharynx.
We additionally included 3,641 generic controls to further increase
the statistical power. These generic controls included: 1,385
individuals from the 1958 birth cohort (Wellcome Trust case
control consortium) [26], as well as 1,823 French and 433
Norwegian controls genotyped by the Centre National Genoty-
page (CNG Evry France). The replication series consisted of 1,046
oral cancer cases (squamous cell carcinomas) and 2,131 controls
from 4 case-control studies (Table S2) [27,28].
Genotyping
Discovery phase (genome-wide genotyping). The CE
study and the ARCAGE study, as well as the generic controls
from Norway and France, were genotyped using the Illumina
Sentrix HumanHap300 BeadChip at the Centre d’Etude du
Polymorphisme Humain (CEPH) and the CNG as previously
described [12,29]. The generic UK controls were genotyped at the
Wellcome trust Sanger Institute using the Illumina HumanHap
550 BeadChip [26].
We conducted systematic quality control steps on the raw
genotyping data. SNPs with a genotype call rate of less than 95%,
as well as individuals where the overall genotype completion rate
was less than 95%, were excluded. We further excluded SNPs for
which the genotype distribution clearly deviated from that
expected by Hardy-Weinberg Equilibrium (HWE) among controls
(p-value,10
27). Also excluded were individuals for which we
observed discrepancies between reported gender and gender based
on genotypes, as well as individuals with unlikely heterozygosity
rates across genetic variants on the X chromosome. Those
genotyped were restricted to individuals of self-reported European
ethnicity. To further increase the ethnic homogeneity of the series,
we used the program STRUCTURE to identify individuals of
mixed ethnicity [30]. Using a subseries of 12,898 genetic variants
from the HumanHap300 BeadChip panel evenly distributed
across the genome and in low linkage disequilibrium (LD)
(r
2,0.004) [31], we estimated the genetic profile of the study
participants compared with individuals of known ethnic origins
(the Caucasian, African and east-Asian individuals genotyped by
the HapMap project). We excluded 34 individuals because of some
evidence of ethnic admixture, indicating that the extent of
admixture within the central Europe and ARCAGE study centers
is limited.
Replication phase (TaqMan genotyping). Replication
genotyping was performed on the 1,046 oral cancer cases and
the 2,131 controls using the TaqMan genotyping platform at
IARC. The robustness of the TaqMan assays (primers and probes
are available upon request) were confirmed by re-genotyping the
CEPH HapMap (CEU) trios and confirming concordance with
HapMap genotypes. All TaqMan assays were found to perform
robustly and genotype concordance rates for duplicate samples
were above 99.5%.
Supporting Information
Figure S1 Comparison of the statistical power when
evaluating the noteworthiness of SNPs by BFDP. These
power calculations assume an evaluation of 300,000 SNPs of
which 20 (Figure S1A) and 500 (Figure S1B) are truly associated
with the outcome and distributed evenly across three prior
categories, respectively. The overall distribution of SNPs across the
three prior categories is assumed to be [87.5%; 10%; 2.5%]. Flat
PO assumes one single prior category.
(TIF)
Figure S2 Quantile-quantile plot for p-values on 2log10
scale.
(TIF)
Table S1 Keywords used to generate AdAPT priors in
the oral cancer GWAS.
(DOC)
Table S2 Participating studies.
(DOC)
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